⏳ Fetching live dividend data...
Home › Calculator › TARO Dividend Calculator 2026
Taro Pharmaceutical Industries Ltd. · NYSE
Price: $42.98 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in TARO → $8.1K in 10 years · $0.04/month
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TARO position with:
Real after-tax yield depends on where you live and how you hold TARO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.65% | 1.85% | $465 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.95% | 1.15% | $395 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.72% | 0.92% | $372 / yr |
| 🇬🇧 UK ISA | 0% | 4.65% | 1.85% | $465 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.24% | 1.44% | $424 / yr |
| 🇨🇦 TFSA | 0% | 4.65% | 1.85% | $465 / yr |
| 🇨🇦 CA Taxable | 25% | 3.49% | 0.69% | $349 / yr |
| 🇦🇺 Super (pension) | 15% | 3.95% | 1.15% | $395 / yr |
| 🇦🇺 AU Taxable | 30% | 3.25% | 0.46% | $325 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.42% | 0.62% | $342 / yr |
| 🇫🇷 FR Taxable | 30% | 3.25% | 0.46% | $325 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
TARO pays quarterly — 4 times per year. Next ex-div: TBD.
How TARO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TARO sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| C-Conversion | 2011-01-18 | 712,500 | $6.00 | $4.28M | ||
| C-Conversion | 2011-01-18 | 712,500 | $6.00 | $4.28M | ||
| C-Conversion | 2011-01-18 | 712,500 | $6.00 | $4.28M | ||
| Buy | 2010-11-04 | 5,159,765 | $16.00 | $82.56M | ||
| Sale | 2010-11-01 | 5,159,765 | $16.00 | $82.56M | ||
| Buy | 2010-10-01 | 2,333,922 | $18.10 | $42.24M | ||
| C-Conversion | 2010-09-24 | 3,712,500 | $6.00 | $22.27M | ||
| Buy | 2010-09-20 | 2,405,937 | $7.75 | $18.65M | ||
| Buy | 2010-09-14 | 29,382 | $7.75 | $227.7K | ||
| C-Conversion | 2010-09-20 | 2,405,937 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TARO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Taro Pharmaceutical Industries Ltd. (TARO) is currently trading at $42.98, 43% below its 52-week high. The current dividend yield is 4.65% based on an annual payout of $2.00 per share.
Taro Pharmaceutical Industries Ltd. (TARO) is a healthcare stock currently trading at $42.98 with a dividend yield of 4.65%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, TARO has grown its dividend at a compound annual rate of 50.0%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever